1Ohmura C,Watada H,Hirose T. Acute onset and worsening of diabetes concurrent with administration of statins[J].Endocrine Journal,2005.369-372.
2Rajpathak SN,Kumbhani DJ,Crandall J. Statin therapy and risk of developing type 2 diabetes:a meta-analysis[J].Diabetes Care,2009.1924-1929.
3Sattar N,Preiss D,Murray HM. Statins and risk of incident diabetes:a collaborative meta-analysis of randomised statin trials[J].The Lancet,2010.735-742.
4Danaei G,García Rodríguez LA,Fernandez Cantero O. Statins and risk of diabetes:an analysis of electronic medical records to evaluate possible bias due to differential survival[J].Diabetes Care,2013.1236-1240.
6Thongtang N,Ai M,Otokozawa S. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation[J].American Journal of Cardiology,2011.387-392.
7Preiss D,Seshasai SR,Welsh P. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy:a meta-analysis[J].Journal of the American Medical Association,2011.2556-2564.
8Wang KL,Liu C J,Chao TF. Statins,risk of diabetes,and implications on outcomes in the general population[J].Journal of the American College of Cardiology,2012.1231-1238.
9Freeman DJ,Norrie J,Sattar N. Pravastatin and the development of diabetes mellitus:evidence for a protective treatment effect in the west of Scotland coronary prevention Study[J].Circulation,2001.357-362.
10Mora S,Glynn RJ,Hsia J. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia:results from the Justification for the Use of Statins in Prevention:An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials[J].Circulation,2010.1069-1077.
